Media Coverage
November 4, 2025
Co-Founders, CEO Jordi Fàbrega and CSO Dr. Josep Prous Jr. discuss CTH120 and its progression into a Phase IIa study following the completion of first-in-human studies.
February 26, 2026
Optimum Perspectives Podcast – Closing the gap on rare diseases in 2026
Co-Founder & CSO Dr. Josep Prous Jr. joins a discussion on addressing unmet needs in rare diseases, including Fragile X syndrome.
March 11, 2026
Co-Founders, CEO Jordi Fàbrega and CSO Dr. Josep Prous Jr. highlight the challenges of developing treatments for brain disorders and the potential of modulating neuroplasticity to address unmet medical needs in CNS disorders.
March 18, 2026
Labiotech – Brain Awareness Week: cutting-edge neuroscience breakthroughs you should know
A look at advances in neuroscience research and the potential of neuroplasticity to support new approaches to treating Fragile X syndrome.
April 17, 2026
An exploration of neuroplasticity modulation as an emerging treatment approach for Fragile X syndrome and other neurodevelopmental disorders.
July 3, 2026
The Medicine Maker – Biopharma Vital Signs, Part 3: Pressure Points
Industry experts address the scientific, regulatory, manufacturing, financial, and commercial pressures shaping the path from drug discovery to market.
July 10, 2026
The Medicine Maker – Biopharma Vital Signs, Part 4: The New Partnership Playbook
Life sciences leaders comment on how biopharma partnerships are shifting from transactional supplier relationships toward more integrated and collaborative models.
July 17, 2026
The Medicine Maker – Biopharma Vital Signs, Part 5: Capabilities for a Changing Landscape
Leaders from across biopharma consider the capabilities needed to make drug development faster, more flexible, and more resilient.
July 23, 2026
NeurologyLive – Advances in Fragile X syndrome therapeutics: Overviewing the pipeline
An overview of the Fragile X syndrome drug development pipeline and candidates currently in clinical trials, including CONNECTA Therapeutics’ lead program, CTH120.
July 24, 2026
The Medicine Maker – Biopharma Vital Signs, Part 6: Advice for Emerging Biotechs
Biopharma leaders share practical guidance for emerging biotech companies navigating development decisions, funding pressures, manufacturing strategies, partner selection, and commercial readiness.
August 27, 2026
BioSpace Denatured podcast – Fragile X at a turning point: Breaking through the clinical bottleneck
Co-Founder & CEO Jordi Fàbrega discusses recent advances and remaining challenges in developing the first approved therapy for Fragile X syndrome.
September 16, 2026
Co-Founder & CSO Dr. Josep Prous Jr. assesses how neuroplasticity, biomarker strategies, disease models, patient selection, and precision medicine could help advance CNS drug development beyond short-term symptom control.
October 9, 2026
Base to Base Biotech Podcast – 79: Fragile X syndrome
Co-Founders, CEO Jordi Fàbrega and CSO Dr. Josep Prous Jr., join a conversation on Fragile X syndrome, current drug development challenges, and the science behind CONNECTA Therapeutics’ lead program, CTH120.